Skip to content

TBPHTHERAVANCE BIOPHARMA INC

CUSIP G8807B106 · common stock

No tracked investor reported shares of THERAVANCE BIOPHARMA INC (TBPH) for Q2 2026. Joel Greenblatt sold out of its position this quarter.

Holders · Q2 2026
0
New holders
0
Value held
$0
Quarter-end price (est.)
—

Investors holding TBPH · Q2 2026

No tracked investor reported shares this quarter.

Sold out this quarter

InvestorPrior weightPrior sharesPrior valueChange
Joel Greenblatt0.00%45,212$733.8KEXIT

History

QuarterHoldersNewSold outValue heldQuarter-end price (est.)
Q2 2026001$0—
Q1 2026100$733.8K$16.23
Q4 2025100$424.3K$18.71
Q3 2024001$0—
Q2 2024100$35.6M$8.48
Q1 2024100$59.1M$8.97
Q4 2023100$83.4M$11.24
Q3 2023100$64M$8.63
Q2 2023100$76.8M$10.35
Q1 2023100$113M$10.85
Q4 2022100$128.1M$11.22
Q3 2022100$136.1M$10.14
Q2 2022100$121.6M$9.06
Q1 2022100$130.4M$9.56
Q4 2021100$150.9M$11.05
Q3 2021100$101.1M$7.40
Q2 2021100$143.9M$14.52
Q1 2021100$178.3M$20.41
Q4 2020100$155.2M$17.77
Q3 2020100$129.1M$14.78
Q2 2020100$195.4M$20.99
Q1 2020100$215.1M$23.11
Q4 2019100$241M$25.89
Q3 2019100$181.3M$19.48
Q2 2019100$152M$16.33
Q1 2019100$211M$22.67
Q4 2018100$238.2M$25.59
Q3 2018100$304.1M$32.67
Q2 2018100$211.1M$22.68
Q1 2018100$225.7M$24.25
Q4 2017100$259.6M$27.89
Q3 2017100$318.7M$34.24
Q2 2017100$369.5M$39.84
Q1 2017100$341.5M$36.82
Q4 2016100$295.7M$31.88
Q3 2016100$266.4M$36.24
Q2 2016100$166.8M$22.69
Q1 2016100$122.2M$18.80
Q4 2015100$105.2M$16.39
Q3 2015100$70.6M$10.99
Q2 2015100$83.6M$13.02
Q1 2015100$110.5M$17.35
Q4 2014100$90.4M$14.92
Q3 2014100$139.7M$23.05
Q2 2014110$193.2M$31.88